CARCINOMA, OVARIAN EPITHELIAL
Clinical trials for CARCINOMA, OVARIAN EPITHELIAL explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, OVARIAN EPITHELIAL trials appear
Sign up with your email to follow new studies for CARCINOMA, OVARIAN EPITHELIAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Ovarian cancer hope: immunotherapy combo shows promise in Tough-to-Treat cases
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has stopped responding to platinum-based treatments. About 643 adults with this type of ovarian cance…
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 05:01 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, melanoma, and kidney cancer. The main goal is to find a safe dose and understand side effects. About 126 participants will take part to see if the treatm…
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
New combo therapy aims to keep ovarian cancer at bay
Disease control OngoingThis study looks at whether adding olaparib to standard bevacizumab maintenance therapy helps women with a specific type of advanced ovarian cancer (HRD-positive) stay cancer-free longer after initial chemotherapy. About 190 participants who have already responded to first-line t…
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE4 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug combo could slow ovarian Cancer's return
Disease control OngoingThis study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated May 18, 2026 12:07 UTC